Zura Bio is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders. Currently, Zura Bio is developing three assets which have completed phase 1/1b studies and are Phase 2 ready. The company is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), torudokimab (ZB-880), and ZB-168 with a goal of demonstrating their efficacy, safety, and dosing convenience in immune and inflammatory disorders. Zura Bio is headquartered in Henderson, NV with team members in the UK and USA. 

Biotechnology

Health Care

Life Sciences

Zura Bio Limited (Nasdaq: ZURA)

Someit Sidhu

Michael Howell

Kiran Nistala

Sandeep Kulkarni

Rob Lisicki

Verender Badial

Kim Davis

Gary Whale

Leadership Team

Operations and Executive Planning

Teams at Zura Bio Limited (Nasdaq: ZURA)

Leadership Team

Operations and Executive Planning